Roche presents new Phase III one-year data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss

In the MEERKAT and SANDCAT studies, vamikibart demonstrated sustained improvements in vision and reductions in macular thickness in patients with UME at 52 weeks1,2UME is the leading cause of moderate and severe vision loss in patients with uveitis, posing a significant risk of blindness if left untreated3,4The FDA has accepted Roche's Biologics License Application (BLA), with an approval decision expected by July 2027 Basel, 10 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today n